rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Kiora Pharmaceuticals, Inc.

KPRX · Nasdaq

Health CareBiotechnologyJust dropped out

KPRX stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 4.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
21 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders21+4 on the quarter
New · exited9 · 5
Reported value$2.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
PERCEPTIVE ADVISORS LLCnew · filed 14 Aug 2026438,471$1.2M+438,471
ADAR1 Capital Management, LLCunchanged · filed 14 Aug 2026167,941$442K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 2026116,011$305K+66,478+134.2%
TWO SIGMA INVESTMENTS, LPnew · filed 14 Aug 202688,792$234K+88,792
MILLENNIUM MANAGEMENT LLCnew · filed 14 Aug 202674,202$195K+74,202
RENAISSANCE TECHNOLOGIES LLCnew · filed 13 Aug 202629,824$78K+29,824
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202626,717$70K-21,133−44.2%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202619,861$52K00.0%
Scientech Research LLCnew · filed 14 Aug 202618,746$49K+18,746
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202613,030$34K00.0%
30 Jun 2024 – 30 Jun 2026
141821Jun 24Dec 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Keith J. Lane Company insiderOther · last 17 Sep 20260 · 0
Brian M. Strem Company insiderPresident and CEO · last 1 Jul 20262 · 0
Melissa Tosca Company insiderCFO · last 1 Jul 20262 · 0
Aron Shapiro Company insiderDirector · last 10 Jun 20261 · 0
Carmine N. Stengone Company insiderDirector · last 10 Jun 20261 · 0
David Hollander Company insiderDirector · last 10 Jun 20260 · 0
Erin Parsons Company insiderDirector · last 10 Jun 20261 · 0
Lisa Walters-Hoffert Company insiderDirector · last 10 Jun 20261 · 0
Praveen Tyle Company insiderDirector · last 10 Jun 20261 · 0
Eric Joseph Daniels Company insiderChief Development Officer · last 1 Apr 20261 · 0
Kenneth L. Gayron Company insiderDirector · last 29 Sep 20230 · 0
Paul G. Chaney Company insiderDirector · last 3 Mar 20231 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-62.2%
Share count trendFY 2025 · to 21 Mar 20265.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$8.7M
Free cash flowFY 2025 · to 31 Dec 2025−$10.1M

Analyst forecasts

No analyst forecasts yet.